

N

*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Naldemedine 200 micrograms film-coated tablets (Rizmoic®) SMC 2242	For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain	Available in line with local guidance for prescribing	180	Sept 2020
Nalmefene 18mg film-coated tablets (Selincro®) (917/13)	The reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL).	Formulary GPs should signpost patients to appropriate services offering psychosocial support such as: Tayside Council on Alcohol (TCA) Addaction (Dundee) Dundee Drug, Alcohol & Blood Borne Virus (BBV) team Perth & Kinross Alcohol & Drug Team Angus Alcohol & Drug Partnership (ADP)	132 131 147	Nov/Dec 2013 Oct /Nov 2013 Apr/May 2015

Naloxegol 12mg and 25mg film-coated tablets (Moventig®) SMC No. 1106/15	Treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).	Formulary Amber - can be prescribed by General Practice under direction of a specialist.	153	Jan/Feb 2016
Naltrexone hydrochloride/bupropion hydrochloride 8mg/90mg prolonged-release tablets (Mysimba®) SMC2086	As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of • ≥ 30 kg/m ² (obese), or • ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).	Not routinely available as not recommended for use in NHS Scotland	169	July 2018
Naproxen (Stirlescent®) 1154/16	As an add-on treatment for severe refractory eosinophilic asthma in adult patients. Restriction: patients who have had eosinophils of at least 150 cells per microlitre (0.15 x 10 ⁹ /L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines (Link to Formulary)	156	Sep 2016
Naproxen/esomeprazole (Vimovo®) (734/11)	Symptomatic treatment of OA, RA and AS	Not recommended	112	Dec 2011
Natalizumab (Tysabri®) (979/14) Superseded by 329/06, see below	Single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for adult patients aged 18 years and over with high disease activity despite treatment with glatiramer acetate .	Not recommended	139	June/July 2014
Natalizumab (Tysabri®) 329/06	Single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) only in patients with	Available in line with local guidance for prescribing	76 Protocol 72	Jan 2008 Sept 2007

	rapidly evolving severe RRMS defined by two or more disabling relapses in one year and with one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.		64	2006
Necitumumab 800mg concentrate for solution for infusion (Portrazza®)	In combination with gembitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced metastatic epidermal growth factor receptor (AGFR) expressing squamous non small cell lung cancer who have not received prior chemotherapy for this condition	Not available as not recommended for use in NHS Scotland	156	Sep 2016
Nebivolol (Nebilet®) (214/05)	Heart failure in patients over 70 years	Non-formulary	72 61	Sept 2007 2006
Nelarabine (Atriance®)	T-ALL and T-LBL		79 78	May 2008 Apr 2008
Nepafenac 3mg/mL eye drops, suspension (Nevanac®) (1228/17)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	Available in line with national guidance Hospital Use Only	161	Jun 2017
Nepafenac (Nevanac®) (813/12)	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	HOSPITAL ONLY (Ophthalmology clinic) Restricted to diabetic patients with diabetic retinopathy undergoing cataract surgery.	122	Dec 2012
Nepafenac (Nevanac®) (588/09)	Prevention and treatment of postoperative pain and inflammation associated with cataract surgery	Not recommended	93	Oct/Nov 2009
Neratinib 40mg film-coated tablets (Nerlynx®) SMC 2251	For the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.	Available in line with local guidance for prescribing	180	Sept 2020

netarsudil plus latanoprost eye drops solution (Roclanda®) SMC2720	<p>for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.</p> <p>SMC restriction: for use in patients for whom treatment with a prostaglandin analogue alone provides insufficient IOP reduction, only if:</p> <ul style="list-style-type: none"> the patient has then tried a fixed-dose combination treatment and it has not sufficiently reduced IOP, or a fixed-dose combination treatment containing beta-blockers is unsuitable <p>In a phase III study, netarsudil plus latanoprost was non-inferior to a prostaglandin analogue plus beta-blocker in mean IOP at week 2, week 6 and month 3.</p>			
Netupitant/palensetron 300mg/0.5mg, hard capsule (Akynzeo®) SMC No. 1109/15	In adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy. SMC Restriction: prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.	Available in line with national guidance	153 157	Jan/Feb 2016 Nov 2016
Nevirapine (Viramune prolonged release tablets®) (760/12)	HIV-1	HOSPITAL ONLY (HIV Clinic)	115	Mar/Apr 2012
Nicotinic acid MR (Niaspan®)	Dyslipidaemia	Not recommended	55 48 38	2006 2005 2004

Nicotinic acid/laropiprant (Tredaptive®)	Dyslipidaemia		96	Apr/May 2010
Nilotinib 150mg and 200mg hard capsules (Tasigna®) SMC No 1325/18	Paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase. Paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.	Not available as not recommended in NHS Scotland	168	May 2018
Nilotinib (Tasigna®) (709/11)	Newly diagnosed Philadelphia positive chronic myelogenous leukaemia (CML)	Non-formulary - pending protocol update	116 109	Apr/May 2012 Sept 2011
Nilotinib (Tasigna®) (440/08)	Chronic phase of Philadelphia positive chronic myelogenous leukaemia (CML)	HOSPITAL ONLY (Haematology)	108 Protocol 80	Aug 2011 June 2008
Nintedanib 100mg and 150mg soft capsules (Ofev®) SMC2331	In adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype other than idiopathic pulmonary fibrosis (IPF).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	185	July 2021
Nintedanib (Ofev®) (1076/15)	For use in adults for the treatment of idiopathic pulmonary fibrosis (IPF).	Non-formulary - pending protocol review	152	Nov/Dec 2015
Nintedanib (Vargatef®) (1027/15)	For the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy	Available in line with national guidance	147 157	Apr 2015 Nov 2016
Niraparib (Zejula) SMC2338	As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following	Available in line with national guidance	185	July 2021

	completion of first-line platinum-based chemotherapy. In a randomised, double-blind, phase III study, niraparib significantly improved progression-free survival compared with placebo.			
Nintedanib soft capsules (Ofev®) SMC2513	In adults for the treatment of idiopathic pulmonary fibrosis (IPF).	Available in line with national guidance	193	
Niraparib tosylate monohydrate 100mg hard capsules (Zejula®) SMC No 1341/18	<p>As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.</p> <p>SMC restriction: to patients who do not have a germline BRCA mutation.</p> <p>Niraparib was assessed in a double blind, randomised, placebo controlled phase III study of patients with high grade serous, recurrent, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in which there had been an objective response to the most recent platinum-based chemotherapy regimen. Niraparib maintenance was associated with a significantly improved progression free survival when compared with placebo.</p>	Available in line with national guidance	170	Sep 2018
Nirmatrelvir and ritonavir (Paxlovid®) SMC2557	Treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19 Restriction: patients who have an increased risk for progression to severe COVID-19, as defined in section 5 of NICE final guidance.	Available in line with national guidance		March 2024 May 2025
Nitisinone 2mg, 5mg, 10mg and 20mg hard capsules and 4mg/ml oral suspension (Orfadin®) SMC2450	Treatment of adult patients with alkaptonuria (AKU).	Not available as not recommended for use in NHS Scotland	188	April 2022

Nivolumab concentrate for solution for infusion (Opdivo®) SMC2704	Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma.	Not recommended for use in NHS Scotland		NYP
Nivolumab, relatlimab concentrate for solution for infusion (Opdualag®) SMC2645	first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.	Available in line with national guidance	198 not yet published	
Nivolumab solution for infusion (Opdivo®) SMC2620	in combination with ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma with tumour cell programmed death ligand (PD-L1) expression $\geq 1\%$	Not available as not recommended for use in NHS Scotland	195	December 2023
Nivolumab concentrate for solution for infusion (Opdivo) SMC2619	in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer in adults.	Available in line with national guidance	196- awaiting publication	Feb 2024
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2503	As monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression $\geq 1\%$, who are at high risk of recurrence after undergoing radical resection of MIUC. In a double-blind, randomised, phase III study, disease-free survival was significantly improved with adjuvant nivolumab compared with placebo in patients with MIUC at high risk of recurrence after surgery.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	192	April 2023
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2458	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5 . In a phase III study, nivolumab in combination with	Available in line with national guidance	191	Nov 2022

	chemotherapy was associated with significantly improved progression-free survival and overall survival compared with chemotherapy alone.			
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2429	<p>As monotherapy for the adjuvant treatment of adult patients with completely resected oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.</p> <p>In one randomised, double-blind, phase III study, nivolumab significantly improved disease-free survival compared with placebo in patients with oesophageal or gastro-oesophageal junction cancer who had complete resection and residual pathologic disease after neoadjuvant chemoradiotherapy.</p>	Available in line with national guidance	189	May 2022
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2385	<p>In combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).</p> <p>In a phase III study of patients with previously untreated, unresectable MPM, overall survival was significantly longer in the nivolumab plus ipilimumab group compared with standard chemotherapy.</p>	Available in line with national guidance	188	April 2022
Nivolumab (Opdivo) NSCLC Bristol-Myers Squibb SMC2397	In combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	Not available as not recommended for use in NHS Scotland	188	April 2022
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2394	<p>In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.</p> <p>In a single-arm cohort of a phase II study, nivolumab in combination with ipilimumab was associated with clinically</p>	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2022

	relevant overall response rates in adults with dMMR or MSI-H metastatic colorectal cancer who had received prior fluoropyrimidine-based chemotherapy.			
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC2362	As monotherapy for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.	Available in line with national guidance	186	Sept 2021
Nivolumab 10mg/ml concentrate for solution for dilution (Opdivo®) SMC2153	In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by September 2019.	175 176	Aug 2019 Oct 2019
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2112	As monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection	Available in line with local guidance for prescribing	173	March 2019
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC No 1285/18	Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy	Not available as not recommended for use in NHS Scotland	167	April 2018
Nivolumab, 10mg/mL concentrate for solution for infusion (Opdivo®) SMC No. (1261/17)	As monotherapy for the treatment of chronic lymphocytic leukaemia (CLL): In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway	Available in line with national guidance	164	Oct 2017
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC No (1240/17)	The treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin	Available in line with national guidance	163	Sep 2017
Nivolumab 10mg/ml	As monotherapy for the treatment of advanced renal cell	Available in line with national	158	Dec 2016

concentrate for solution for infusion (Opdivo®) SMC 1188/16	carcinoma after prior therapy in adults.	guidance	162	Aug 2017
Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®) SMC 1187/16	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults. SMC restriction: for the first-line treatment of advanced melanoma	Available in line with national guidance	158	Dec 2016
Nivolumab, 10mg/ml, concentrate for solution for infusion (Opdivo®) SMC 1180/16	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Available in line with national guidance	158	Dec 2016
Nivolumab (Opdivo®)1144/16	Treatment of locally advanced or metastatic squamous non small cell lung cancer after prior chemotherapy in adults.	Available in line with National Guidance	156	Sep 2016
Nivolumab 10mg/mL, concentrate for solution for infusion (Opdivo®) 1120/16	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Available in line with national guidance	154 155 156	May 2016 June 2016 Sep 2016
Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®) SMC2519	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression $\geq 1\%$.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Nomegestrol acetate/estradiol (Zoely®) (898/13)	Oral contraception	Not recommended	129	Aug/Sept 2013
Norelgestomic/ethinyloest	Female contraception		31	2003

radiol patch (Evra®)				
Nusinersen 12mg solution for injection (Spinraza®) SMC No 1318/18	For the treatment of 5q spinal muscular atrophy (SMA). SMC Restriction: patients with symptomatic type 1 SMA (infantile onset)).	Available in line with national guidance	169	July 2018

Updated: 30th June 2025

[Back to top](#)

[Back to homepage](#)